Novasep has announced a further expansion of its HPAPIs manufacturing capabilities on its Le Mans site. The step is aimed to reinforce the company’s position as a CDMO for the production of targeted molecules to treat cancer.
This site, which has already received investment, continues to exhibit growth as a result of collaborations with pharmaceutical companies & partnerships with biotechnology innovators, the company claims. To support this growth and the increase in both clinical & commercial production capacity, the company is recruiting more than 30 people on this site, combined with an investment of more than $4.83 m.
Novasep has been a partner to companies in the ADC arena for more than 15 years. The company’s bioconjugation facility, launched in 2017 with an investment of $14.5 m, delivers cGMP ADC batches to customers and has been inspected by the ANSM (French regulatory drug authorities) in 2021.
Dr Michel Spagnol, Chair and CEO of Novasep said "We are pleased to continue our development in strategic markets such as HPAPIs and ADCs, and to participate in the fight against cancer for the benefit of patients. Specifically, this expansion allows us to create more than 30 full-time jobs in Le Mans.”
